WISeKey's WISe.ART 3.0, One of the World's First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN's MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30
WISeKey's WISe.ART 3.0, One of the World's First and Largest Web3 Marketplaces for Digital Art, Twins, NFTs, and Crypto Collectibles will be Presenting FABEN's MLove at NFC Lisbon on June 5 on the Alpha Stage at 4:30 pm
Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options for over 10 million patients[1] - Sandoz Group ( OTC:SDZNY )
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules WYOST® ( denosumab-bbdz ) and Jubbonti® ( denosumab-bbdz ) are first and only FDA-approved interchangeable denosumab biosimilars available in US
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology ...
WISeKey to Present at Maxim Tech Conference "Discover the Innovations Reshaping Tomorrow" on June 3 at 8:30am ET
WISeKey to Present at Maxim Tech Conference "Discover the Innovations Reshaping Tomorrow" on June 3 at 8:30am ET
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology ...
AVTL successfully completed IPO
Rotterdam, the Netherlands, 02 June 2025 Today, we announce an update regarding the primary equity issue of our joint venture AVTL. AVTL has successfully completed its IPO. The issue price for the IPO was INR 235 per share which is at the top end of the previously announced price band.
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology ...
Elon Musk Says DOGE Became A 'Whipping Boy' For Everything Real Or Imagined - Tesla CEO Doesn't Agree With Everything White House Does But Won't Speak Out: 'Creates A Bone Of Contention' - Tesla ( NASDAQ:TSLA )
Tesla Inc. TSLA CEO Elon Musk has defended his controversial tenure at the Department of Government Efficiency, stating that it became a scapegoat for everything wrong in Washington.
